A Phase 2b, Open-label Study to Evaluate the Immunogenicity and Safety of Hecolin in HIV Positive/Negative Adult Participants Followed by a Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Immunogenicity and Safety of Hecolin in Children
Latest Information Update: 09 May 2025
At a glance
- Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary) ; Sodium chloride
- Indications Hepatitis E
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 29 Apr 2025 Planned number of patients changed from 860 to 1040.
- 29 Apr 2025 Status changed from not yet recruiting to recruiting.
- 18 Mar 2024 New trial record